Resumen de Peficitinib hydrobromide to treat rheumatoid arthritis.

Sergio Ramón Gutiérrez Ureña, E.L. Amaya Cabrera, J.F. Uribe Martínez, M.E. Ventura Valenzuela, C. Rosal Arteaga, G.E. Martínez Bonilla, V. González Díaz, O. Almengor Montenegro, S. Cerpa Cruz

• Peficitinib hydrobromide is a small Janus kinase inhibitor (JAK1, JAK2, JAK3 and TYK2) molecule for the treatment of rheumatoid arthritis (RA). Phase II and phase III clinical trials and extension studies with different doses have been conducted to assess the drug’s efficacy and safety with substantially improved outcomes observed in RA. This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX. The findings from studies of this new JAK inhibitor have shown that, both in monotherapy as well as in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), it has efficacy, safety and tolerability in RA patients.